PARTNERING

Rodos partners with pharmaceutical and biotechnology companies for improved delivery of their novel drug candidates. Our proprietary TargoSphere® delivery platform allows us to reformulate established agents or new drugs which will provide improved and sustained delivery, repositioning and/or repurposing for life-cycle extension.

TargoSphere® advantages over conventional nanocarriers:

  • Provide exclusive targeted drug delivery mode of action, specific for a preselected cell species or class of cells;
  • Good preclinical safety profile;
  • Completely biodegradable and biocompatible;
  • Able to deliver payloads with hydrophilic and lipophilic properties. Payloads may include small drug molecules, proteins, peptides, and nucleic acids (plasmid DNA, mRNA, siRNA) and others;
  • Administration via different routes.

 

CUSTOMER VALUE

 

  • Increased bioavailability enabling crossing of biological barriers and cellular membranes
  • Protection of loaded drugs from immunological attacks and the induction of drug-specific immunity;
  • Protection of the payload from enzymatic degradation and/or rapid excretion;
  • Prevention/reduction of drug-related adverse events;
  • Improved drug activity at significantly lower doses leads to lower of COGS;
  • Broad opportunities for life cycle management by extending/ revising applications of approved drugs;
  • Environmental compatibility due to our nanocarriers’ natural and biodegradable components.

We are happy to explore strategic commercial partnership and co-development opportunities that advance our mission of improving the lives of patients suffering from serious diseases. If you are interested in partnering with Rodos Biotarget, please contact us to reach our Business Development team.

businessdevelopment@biotargeting.eu

PIPELINETogether with industrial partners, we are currently developing a highly diversified portfolio of TargoSphere® applications, including treatments against chronic infectious diseases (e.g., HIV, HCV), infectious and non-infectious liver diseases, cancers, immune disorders such as multiple sclerosis and neurodegenerative disorders such as Alzheimer’s disease. We are also developing prophylactic vaccinations.

 

THE EMERGING PIPELINE OF TARGOSPHERE APPLICATIONS ACTIVE PROGRAMS / STATUS: MAY 2016

programs

SPECIAL PURPOSE PARTNERING OPPORTUNITIES

ORGAN PERFUSION SYSTEM ORGANPROTECT®

Co-developed with the University of Essen Medical School, our novel proprietary organ perfusion system – OrganProtect® – stands out by maintaining excellent functional characteristics of the perfused tissue for prolonged times.

Examples of use:

  • Demonstration of target cell-specific delivery of TargoSphere®-encased therapeutics within structurally and functionally intact human liver tissue;
  • Ex vivo emulation of functional in vivo conditions in non-cirrhotic and cirrhotic human liver;
  • Reliable testing of early events in acute liver failure (ALF) upon drug challenge.

OrganProtect® applications:

  • Organ transplants: Prolonged functional preservation and transport;
  • Ex vivo safety/toxicity testing of new drug or drug–nanocarrier candidates.

Rodos is eager to co-develop these opportunities in collaboration with clinical transplantation departments and specialized medical device companies.

We look forward to hearing from you.

 

AUGUSTUS BIOTARGET, INC.

Rodos Biotarget GmbH has entered into a collaborative project agreement with Augustus BioTarget, Inc. in the USA, in which Rodos is providing its proprietary CLR-TargoSphere® for the encapsulation and delivery of antiproliferative and anti-inflammatory agents provided by Augustus BioTarget for preclinical and clinical development of treatments for Alzheimer’s disease, among others.

The project is funded in the USA. For further detail, please visit http://augustusbiotarget.com
If you are interested in this project, we look forward to hearing from you at: businessdevelopment@biotargeting.eu

Back To Top